We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat
Read MoreHide Full Article
Shares of Change Healthcare Inc. have gained 1.9% as of Aug 12, 2020 driven by better-than-expected fiscal first-quarter performance.
The company reported first-quarter fiscal 2021 adjusted earnings per share of 25 cents, which beat the Zacks Consensus Estimate by 66.7%. However, the bottom line declined 55.4% year over year.
Revenue Details
Revenues declined 18.9% from the prior-year period to $694.2 million in the reported quarter. However, the top line surpassed the Zacks Consensus Estimate by 7.3%.
Segmental Analysis
Change Healthcare operates through three segments — Software and Analytics, Network Solutions, and Technology-Enabled Services.
Software and Analytics
Revenues at this segment totaled $391.6 million, down 9.7% on a year-over-year basis.
Change Healthcare Inc. Price, Consensus and EPS Surprise
Revenues at this segment were $142.8 million, up 0.9% year over year.
Technology-Enabled Services
Revenues at this segment came in at $187.7 million, down 24.2% year over year.
Margin Analysis
Total operating expenses were $701.9 million, down 0.2% from the prior-year quarter.
In the quarter under review, Change Healthcare reported operating loss of $7.7 million, against the year-ago operating income of $152.3 million.
Financial Position
The company exited the quarter with cash and cash equivalents of $178.4 million compared with $410.4 million in the preceding quarter.
Cash used in operating activities at the end of first-quarter fiscal 2021 amounted to $169.1 million compared with cash flow from operating activities of $84.5 million in the year-ago period.
Guidance
Due to uncertainty surrounding the COVID-19 pandemic, Change Healthcare has only issued quarterly guidance.
For second-quarter fiscal 2021, the company projects Solutions revenues between $670 million and $690 million. The Zacks Consensus Estimate for the same is pegged at $731.7 million.
Adjusted EPS is estimated between 20 cents and 23 cents. The Zacks Consensus Estimate for the same stands at 18 cents.
Wrapping Up
Change Healthcare exited first-quarter fiscal 2021 on a strong note, with both earnings and revenues beating the Zacks Consensus Estimate. The Network Solutions recorded solid performance in the quarter under review. Strong guidance also instills investor optimism in the stock.
During the quarter under review, the company launched Connected Consumer Health suite — an innovative new consumer and financial engagement platform partnership with Adobe and Microsoft — that will offer healthcare providers a modern, simplified experience throughout the patient journey.
Also, Change Healthcare introduced nationwide Clinical Data Retrieval service, a new cloud-based interoperability solution, which can help payers to retrieve patient records from the industry’s leading electronic health record systems and other systems in a quick and easy manner.
Additionally, the company offered open access to the Clinical Network lab service, which can allow providers to quickly order COVID-19 tests and other lab tests, thereby expediting diagnostic results for patients nationwide.
These developments have impacted the company’s overall performance and are likely to accelerate growth in the near term.
However, cut-throat competition remains a concern. Also, weak performance of the Software and Analytics, and Technology-Enabled Services segments is a woe.
Zacks Rank
Currently, Change Healthcare carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and West Pharmaceutical Services, Inc. (WST - Free Report) . While PerkinElmer sports a Zacks Rank of 1 (Strong Buy), both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion surpassed the consensus mark by 0.1%.
West Pharmaceuticals reported second-quarter 2020 adjusted EPS of $1.25, outpacing the Zacks Consensus Estimate of 91 cents. Revenues of $527.2 million surpassed the consensus estimate by 6.9%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat
Shares of Change Healthcare Inc. have gained 1.9% as of Aug 12, 2020 driven by better-than-expected fiscal first-quarter performance.
The company reported first-quarter fiscal 2021 adjusted earnings per share of 25 cents, which beat the Zacks Consensus Estimate by 66.7%. However, the bottom line declined 55.4% year over year.
Revenue Details
Revenues declined 18.9% from the prior-year period to $694.2 million in the reported quarter. However, the top line surpassed the Zacks Consensus Estimate by 7.3%.
Segmental Analysis
Change Healthcare operates through three segments — Software and Analytics, Network Solutions, and Technology-Enabled Services.
Software and Analytics
Revenues at this segment totaled $391.6 million, down 9.7% on a year-over-year basis.
Change Healthcare Inc. Price, Consensus and EPS Surprise
Change Healthcare Inc. price-consensus-eps-surprise-chart | Change Healthcare Inc. Quote
Network Solutions
Revenues at this segment were $142.8 million, up 0.9% year over year.
Technology-Enabled Services
Revenues at this segment came in at $187.7 million, down 24.2% year over year.
Margin Analysis
Total operating expenses were $701.9 million, down 0.2% from the prior-year quarter.
In the quarter under review, Change Healthcare reported operating loss of $7.7 million, against the year-ago operating income of $152.3 million.
Financial Position
The company exited the quarter with cash and cash equivalents of $178.4 million compared with $410.4 million in the preceding quarter.
Cash used in operating activities at the end of first-quarter fiscal 2021 amounted to $169.1 million compared with cash flow from operating activities of $84.5 million in the year-ago period.
Guidance
Due to uncertainty surrounding the COVID-19 pandemic, Change Healthcare has only issued quarterly guidance.
For second-quarter fiscal 2021, the company projects Solutions revenues between $670 million and $690 million. The Zacks Consensus Estimate for the same is pegged at $731.7 million.
Adjusted EPS is estimated between 20 cents and 23 cents. The Zacks Consensus Estimate for the same stands at 18 cents.
Wrapping Up
Change Healthcare exited first-quarter fiscal 2021 on a strong note, with both earnings and revenues beating the Zacks Consensus Estimate. The Network Solutions recorded solid performance in the quarter under review. Strong guidance also instills investor optimism in the stock.
During the quarter under review, the company launched Connected Consumer Health suite — an innovative new consumer and financial engagement platform partnership with Adobe and Microsoft — that will offer healthcare providers a modern, simplified experience throughout the patient journey.
Also, Change Healthcare introduced nationwide Clinical Data Retrieval service, a new cloud-based interoperability solution, which can help payers to retrieve patient records from the industry’s leading electronic health record systems and other systems in a quick and easy manner.
Additionally, the company offered open access to the Clinical Network lab service, which can allow providers to quickly order COVID-19 tests and other lab tests, thereby expediting diagnostic results for patients nationwide.
These developments have impacted the company’s overall performance and are likely to accelerate growth in the near term.
However, cut-throat competition remains a concern. Also, weak performance of the Software and Analytics, and Technology-Enabled Services segments is a woe.
Zacks Rank
Currently, Change Healthcare carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks in the broader medical space are Thermo Fisher Scientific Inc. (TMO - Free Report) , PerkinElmer, Inc. and West Pharmaceutical Services, Inc. (WST - Free Report) . While PerkinElmer sports a Zacks Rank of 1 (Strong Buy), both Thermo Fisher and West Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PerkinElmer reported second-quarter 2020 adjusted EPS of $1.57, surpassing the Zacks Consensus Estimate by 68.8%. Revenues of $811.7 million outpaced the consensus mark by 1.3%.
Thermo Fisher reported second-quarter 2020 adjusted EPS of $3.89, beating the Zacks Consensus Estimate by 45.7%. Revenues of $6.92 billion surpassed the consensus mark by 0.1%.
West Pharmaceuticals reported second-quarter 2020 adjusted EPS of $1.25, outpacing the Zacks Consensus Estimate of 91 cents. Revenues of $527.2 million surpassed the consensus estimate by 6.9%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>